XY03 EA
Alternative Names: XY03-EALatest Information Update: 21 Sep 2022
At a glance
- Originator Shijiazhuang Yiling Pharmaceutical
- Class Benzofurans; Butyric acids; Esters; Ketones; Neuroprotectants; Small molecules; Vascular disorder therapies
- Mechanism of Action Autophagy inhibitors; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Stroke
Most Recent Events
- 25 Aug 2022 Phase-I clinical trials in Stroke in China (PO) prior to August 2022 (Shijiazhuang Yiling Pharmaceutical pipeline, August 2022)
- 25 Aug 2022 Shijiazhuang Yiling Pharmaceutical plans a phase II trial for Sroke in October 2022 (PO) (NCT05515393)
- 30 Mar 2022 Pharmacodynamics data from a preclinical trial in Stroke released by Shijiazhuang Yiling Pharmaceutical